NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

THTX

Theratechnologies Inc

Jun 30 • 04:00PM ET

2.36

Dollar change +0.01
Percentage change 0.43	%

Healthcare • Biotechnology • Canada • NASD

Peers: REGN VRTX BIIB BMRN SRPT NBIX RARE PBYI ARDX ENTA

| Held by: DFIC DFAX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.09	Insider Own	20.99%	Shs Outstand	45.98M	Perf Week	-4.07%
Market Cap	108.51M	Forward P/E	8.14	EPS next Y	0.29	Insider Trans	0.00%	Shs Float	36.33M	Perf Month	-9.23%
Enterprise Value	154.52M	PEG	-	EPS next Q	-0.01	Inst Own	27.85%	Short Float	0.66%	Perf Quarter	57.33%
Income	-3.71M	P/S	1.22	EPS this Y	155.88%	Inst Trans	-8.08%	Short Ratio	0.11	Perf Half Y	29.23%
Sales	88.67M	P/B	-	EPS next Y	205.26%	ROA	-5.77%	Short Interest	0.24M	Perf YTD	30.39%
Book/sh	-0.53	P/C	25.00	EPS next 5Y	-	ROE	-	52W High	3.13 -24.60%	Perf Year	52.26%
Cash/sh	0.09	P/FCF	-	EPS past 3/5Y	50.34% 23.68%	ROIC	-17.43%	52W Low	1.12 110.71%	Perf 3Y	-73.78%
Dividend Est.	-	EV/EBITDA	10.32	Sales past 3/5Y	7.14% 6.32%	Gross Margin	77.60%	Volatility	4.51% 3.74%	Perf 5Y	-74.89%
Dividend TTM	-	EV/Sales	1.74	EPS Y/Y TTM	90.91%	Oper. Margin	13.81%	ATR (14)	0.11	Perf 10Y	-45.04%
Dividend Ex-Date	-	Quick Ratio	0.88	Sales Y/Y TTM	13.52%	Profit Margin	-4.18%	RSI (14)	37.17	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.08	EPS Q/Q	102.36%	SMA20	-5.77%	Beta	0.56	Target Price	3.87
Payout	-	Debt/Eq	-	Sales Q/Q	17.23%	SMA50	-9.56%	Rel Volume	0.03	Prev Close	2.35
Employees	105	LT Debt/Eq	-	Earnings	Apr 09 BMO	SMA200	32.36%	Avg Volume	2.14M	Price	2.36
IPO	Nov 04, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	-100.00% -6.68%	Trades		Volume	67,061	Change	0.43%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-17-22	Initiated	Cantor Fitzgerald	Overweight	$9
Jul-29-21	Downgrade	Canaccord Genuity	Buy → Hold	$8 → $3

May-29-25 02:00PM	Theratechnologies Reports on its Annual Meeting of Shareholders (GlobeNewswire)
May-02-25 07:30AM	Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV (GlobeNewswire) -5.14%
Apr-18-25 03:12PM	Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts? (Insider Monkey)
12:01PM	Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer (Seeking Alpha)
Apr-15-25 06:00PM	Theratechnologies Provides Update on Sale Process (GlobeNewswire)
10:00AM	Loading…
Apr-12-25 10:00AM	Future Pak submits proposals to acquire Theratechnologies (TipRanks)
08:46AM	Soleus Capital Issues Letter to The Board of Theratechnologies (Business Wire)
Apr-11-25 05:00PM	Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company (GlobeNewswire) +45.86% +32.47%
02:58PM	Theratechnologies Shares Jump 42% After Future Pak's $255 Million Takeover Bid (GuruFocus.com)
09:57AM	Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value (Business Wire)
Apr-10-25 03:00AM	Theratechnologies Inc (THTX) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) -6.34%
Apr-09-25 10:28AM	Theratechnologies Inc. (THTX) Q1 2025 Earnings Call Transcript (Seeking Alpha) -8.39%
07:30AM	Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements (GlobeNewswire)
Apr-08-25 07:00AM	Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV sBLA (GlobeNewswire) -5.49%
Apr-03-25 04:30PM	Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update (GlobeNewswire)
05:45PM	Loading…
Mar-25-25 05:45PM	Theratechnologies Receives FDA Approval for EGRIFTA WR (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy (GlobeNewswire) +20.78%
Mar-12-25 07:30AM	Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI (GlobeNewswire)
07:30AM	Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV (GlobeNewswire)
Feb-27-25 02:09AM	Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ... (GuruFocus.com)
Feb-26-25 07:54AM	Theratechnologies: Fiscal Q4 Earnings Snapshot (Associated Press Finance) -11.85%
07:30AM	Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024 (GlobeNewswire)
Feb-25-25 11:02AM	Theratechnologies Inc (TSX:TH) Q4 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Feb-14-25 07:30AM	Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update (GlobeNewswire) +7.36%
Feb-13-25 07:45PM	Theratechnologies Resumes Distribution of EGRIFTA SV (GlobeNewswire)
Jan-09-25 05:05PM	Theratechnologies Provides Update on EGRIFTA SV Supply (GlobeNewswire)
Dec-18-24 01:30PM	Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV Manufacturing Environment (GlobeNewswire) +9.26%
Dec-10-24 03:15PM	Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA (GlobeNewswire) -9.68%
Dec-09-24 07:30AM	Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer (GlobeNewswire) +9.15%
Dec-05-24 07:35AM	Theratechnologies enters exclusive licensing agreement with Ionis (TipRanks) +5.63%
06:59AM	Theratechnologies to license Ionis' RNA-targeted therapies in Canada (Pharmaceutical Business Review)
07:30AM	Loading…
Dec-04-24 07:30AM	Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada (GlobeNewswire) +7.17%
Dec-03-24 04:30PM	Theratechnologies Announces Resumed Production of EGRIFTA SV (GlobeNewswire)
07:47AM	Theratechnologies secures up to $75M in new credit facilities (TipRanks)
Dec-02-24 07:30AM	Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Quebec (GlobeNewswire) +6.61%
07:30AM	Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Qu bec (GlobeNewswire)
Nov-26-24 07:30AM	Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review (GlobeNewswire)
Oct-17-24 02:00PM	Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV (GlobeNewswire)
07:30AM	Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance (GlobeNewswire)
Oct-11-24 03:01AM	Theratechnologies Inc (THTX) Q3 2024 Earnings Call Highlights: Strong Profitability Amid ... (GuruFocus.com)
Oct-10-24 07:45AM	Theratechnologies: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024 (GlobeNewswire)
Oct-09-24 09:02AM	Earnings to Watch: Theratechnologies Inc (TSX:TH) Reports Q3 2024 Result (GuruFocus.com)
07:30AM	Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV (GlobeNewswire)
Sep-26-24 07:30AM	Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update (GlobeNewswire)
Sep-19-24 12:38PM	Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays (Benzinga)
Sep-17-24 05:00PM	Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV in Early 2025 (GlobeNewswire) -12.41%
Sep-09-24 07:30AM	Theratechnologies to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-01-24 08:50AM	Why Fast-paced Mover Theratechnologies (THTX) Is a Great Choice for Value Investors (Zacks)
Jul-16-24 08:50AM	Despite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain Stock (Zacks)
Jul-10-24 12:52PM	THTX Stock Earnings: Theratechnologies Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
09:20AM	HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars (Benzinga)
08:57AM	Theratechnologies: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024 (GlobeNewswire)
Jun-26-24 07:30AM	Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update (GlobeNewswire) +19.23%
Jun-05-24 08:50AM	Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
May-23-24 05:00PM	Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors (GlobeNewswire)
May-09-24 04:30PM	Theratechnologies Reports on its Annual Meeting of Shareholders (GlobeNewswire)
May-02-24 07:30AM	Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting (GlobeNewswire)
Apr-23-24 12:00PM	Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-15-24 04:15PM	Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders (GlobeNewswire) -8.45%
Apr-11-24 07:30AM	Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire)
Apr-10-24 11:52AM	THTX Stock Earnings: Theratechnologies Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:21AM	Theratechnologies: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024 (GlobeNewswire)
Apr-08-24 04:30PM	Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology Oncology Platform (GlobeNewswire) +6.21%
Apr-05-24 11:00AM	Theratechnologies Appoints Elina Tea to its Board of Directors (GlobeNewswire)
Apr-03-24 07:30AM	Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update (GlobeNewswire)
Mar-28-24 07:30AM	Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform (GlobeNewswire) +13.70%
Mar-22-24 09:36AM	Theratechnologies Announces Update on its Preclinical Oncology Research Program (GlobeNewswire)
Mar-21-24 08:00PM	Theratechnologies Appoints Jordan Zwick to its Board of Directors (GlobeNewswire)
07:30AM	Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer (GlobeNewswire)
Feb-29-24 04:34PM	Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau (GlobeNewswire)
Feb-27-24 07:30AM	Theratechnologies Receives Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from FDA (GlobeNewswire)
Feb-26-24 08:50AM	Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Feb-21-24 08:45AM	Theratechnologies: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance (GlobeNewswire)
Feb-20-24 07:30AM	Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action (GlobeNewswire)
Feb-15-24 07:30AM	Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer (GlobeNewswire)
Feb-06-24 07:30AM	Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update (GlobeNewswire) +5.10%
Jan-24-24 07:00AM	Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA (GlobeNewswire) -13.95%
Jan-23-24 07:30AM	Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application (GlobeNewswire) -7.03%
Jan-02-24 07:30AM	Theratechnologies Submits sBLA for Trogarzo Intramuscular (IM) Method of Administration to FDA (GlobeNewswire)
Dec-21-23 04:09PM	Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement (PR Newswire) +5.30%
Dec-19-23 05:08AM	3 Biotech Stock Buys to Boost and Supercharge Portfolios (Entrepreneur: Stocks)
Dec-13-23 07:30AM	Theratechnologies Announces FDA Approval of Trogarzo 90-Second Intravenous (IV) Push Loading Dose (GlobeNewswire)
Nov-24-23 07:30AM	Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award (GlobeNewswire) +13.33%
Oct-31-23 12:34PM	Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement (GlobeNewswire)
Oct-26-23 09:11AM	Why Is Theratechnologies (THTX) Stock Down 22% Today? (InvestorPlace) -28.05%
08:00AM	Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement (GlobeNewswire)
Oct-25-23 04:13PM	Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement (GlobeNewswire)
Oct-24-23 07:00AM	Theratechnologies Announces Operational Update (GlobeNewswire) -10.95%
Oct-19-23 07:30AM	Theratechnologies' Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV (GlobeNewswire)
Oct-16-23 07:30AM	Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon (GlobeNewswire)
Oct-13-23 07:30AM	Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs) (GlobeNewswire)
07:00AM	Theratechnologies Announces Results from Trogarzo (Ibalizumab-uiyk) Intramuscular Administration Study (GlobeNewswire)
Oct-12-23 07:30AM	Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer (GlobeNewswire)
Oct-04-23 07:30AM	Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA (GlobeNewswire)
Sep-26-23 07:47AM	Theratechnologies: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -16.19%
07:30AM	Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates (GlobeNewswire)
Sep-25-23 07:30AM	Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility (GlobeNewswire)

Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montreal, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

THTX

Theratechnologies Inc

Upgrade your FINVIZ experience